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Abstract: A determination method for 3-methylpyrazole-5-carboxylic acid (MPC), an
inhibitor of D-amino acid oxidase (DAAO), in rat plasma was developed by using high-performance
liquid chromatography-mass spectrometry (LC-MS). The structural isomer of MPC, 3-methylpyr-
azole-4-carboxylic acid, was used as an internal standard, and the intra- and inter-day accuracies
and precisions were satisfactory for the determination of plasma MPC.
Next, the LC-MS method was applied to determine the plasma MPC concentration in ketamine
(Ket)-treated rats after intraperitoneal administration of MPC (5.0 or 50mg·kg!1). The Cmax value
of plasma MPC concentration in the Ket-treated rats was signiﬁcantly higher than that in the
control group when a high dose of MPC (50mg·kg!1) was administered. In addition, it was found
that plasma D-tryptophan (D-Trp) concentration in Ket-treated rats administered D-Trp was not
signiﬁcantly increased by MPC, suggesting that the DAAO-inhibitory eﬀect of MPC is attenuated
in Ket-treated rats.
Keywords: 3-methylpyrazole-5-carboxylic acid, D-amino acid oxidase, inhibitor, rat,
ketamine, D-tryptophan
Introduction
Schizophrenia, a serious neuropsychiatric dis-
ease, aﬀects 1% of the general population and
consists of positive symptoms, negative symptoms,
and cognitive impairments.1) The glutamate hypoth-
esis of schizophrenia states that the etiology of
schizophrenia is associated with hypofunction of
NMDA receptor.2) Phencyclidine [1-(1-phenylcyclo-
hexyl)piperidine, PCP], an illicit drug, can act as
non-competitive antagonist for an ionotropic gluta-
mate receptor, the N-methyl-D-aspartate (NMDA)
receptor, and an acute administration of PCP caused
schizophrenia-like symptoms in human.3) This ﬁnd-
ing suggested that blockage of glutamatergic neuro-
transmission via NMDA receptor was related with
the onset of symptoms in schizophrenia. With regard
to current therapeutic drug, it has been reported that
available antipsychotics could improve only positive
symptoms of schizophrenia.4) On the other hand,
D-serine acts as an endogenous co-agonist at the
glycine binding site of the NMDA receptor,5) and
D-serine administration is considered as an eﬀective
therapeutic treatment for schizophrenia. In fact, Tsai
et al. reported that co-administration of D-serine
with the antipsychotics was eﬀective for treating
positive symptoms, negative symptoms, and cogni-
tive impairments in patients with schizophrenia.6)
From these reports, a drug-induced facilitation of
NMDA receptor may take eﬀect for the treatment of
schizophrenia.
In 1994, it was reported that the intake of the
anesthetic drug ketamine (Ket), which acts as a
noncompetitive antagonist of the NMDA receptor,
induced schizophrenia-like symptoms in humans.7)
This ﬁnding suggests that Ket can be used to
produce an experimental model of schizophrenia,
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et al. reported that sub-chronic administration of
a sub-anesthetic dose of Ket (30mg·kg!1)t o
Sprague-Dawley (SD) rats exhibited some changes
in rat behaviors, such as disruption of latent
inhibition and decrease in non-aggressive behavior.9)
In addition, an increase in hippocampal D2 receptor
binding was observed in the Ket-treated rat.9)
These alterations indicated that the Ket-treated
rat could be used, in part, for an animal model
of schizophrenia. Recently, Watanabe et al. also
reported that Ket-treated rats exhibited abnormal
behaviors, including turning, weaving, and head-
bobbing.10)
Recently, it has been reported that a single
administration of Ket caused a dose-dependent and
transient elevation in the levels of serine racemase
(SR) and D-amino acid oxidase (DAAO) mRNA in
all areas within the SD rat brain.11) In contrast,
sub-chronic administration of Ket (50mg·kg!1 daily
for 14 days) decreased the mRNA expression of SR
in rat brain.10) These reports suggest that there
are some links between gene expression of SR or
DAAO mRNA and the blockade of NMDA receptors
by ketamine treatment. It has been found that
brain DAAO activity in schizophrenia patients
was higher than that in a control group.12) DAAO13)
plays a crucial role in the oxidative decomposition
of D-serine, and therefore, an inhibition of DAAO
by a drug may increase D-serine concentration in
the brain tissue to induce facilitation of NMDA
receptor.
Based on these considerations, it has been
proposed that a speciﬁc inhibitor of DAAO may be
therapeutic for the treatment of schizophrenia.14),15)
In 2008, Adage et al. reported the pharmacological
proﬁles of 3-methylpyrazole-5-carboxylic acid (MPC)
(Fig. 1) as an inhibitor of DAAO and that MPC was
able to increase brain D-serine levels and ameliorate
PCP-induced abnormal behavior in SD rats,16)
suggesting that MPC can inhibit DAAO activity
in vivo and is a potential therapeutic drug for the
treatment of schizophrenia. Our recent studies also
indicated that pre-administration or infusion with
MPC inhibited the metabolism of D-tryptophan
(D-Trp)17),18) or D-kynurenine19),20) by DAAO in SD
rats.
Until now, there has been little information on
the pharmacokinetics of MPC in the animal model of
schizophrenia.
In the present study, we investigated time-
course proﬁles of MPC concentration in the plasma
of Ket-treated rats after administration of MPC
by using HPLC with mass spectrometric detection
(MS). The pharmacokinetic parameters were deter-
mined and compared between control and Ket-
treated rats. In addition, the eﬀect on inhibition of
DAAO activity by MPC in Ket-treated rats was also
examined. As a representative substrate for DAAO,
D-Trp (Km value, 845µM)21) was administered to
control and Ket-treated rats that were pretreated
with MPC, and the pharmacokinetic data on plasma




ylic acid, used as an internal standard (I.S.), and
phosphate buﬀered saline (PBS) were obtained from
Sigma-Aldrich (St. Louis, MO). Polyethylene glycol
200 (PEG) was obtained from Tokyo Chemical
Industry Co., Ltd. (Tokyo, Japan). Methanol
(MeOH) and acetonitrile (CH3CN) were obtained
from Kanto Chemical Co. Ltd. (Tokyo, Japan).
Water was used after puriﬁcation by a WR600G
(Nihon Millipore K.K., Tokyo, Japan).
Animal experiments. All animal experiments
were approved (No. 11-55-17) by the Committee of
Animal Care, Toho University. Male SD rats were
purchased from Charles River Japan (Kanagawa,
Japan) and were housed in an environmentally
controlled room for at least 1 week before use.
Administration of Ket to rats was carried out
as previously reported.9) Ketamine hydrochloride
(Wako Pure Chemicals Co., Ltd., Osaka, Japan)
was dissolved in physiological saline (1.0mg·mL!1)
and then intraperitoneally (i.p.) administered (30
mg·kg!1) to 7-week-old rats daily for 5 consecutive
days. The control animals received only saline
(1mL·kg!1·day!1). The rats were used for experi-
ments 4 weeks after cessation of the ketamine or
saline treatment.
Fig. 1. Chemical structures of 3-methylpyrazole-5-carboxylic
acid (MPC) and 3-methylpyrazole-4-carboxylic acid (I.S.).
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(5.0 or 50mg·kg!1·3mL!1) was prepared in PBS/
ethanol/PEG (2.8/0.1/0.1) and was i.p. adminis-
tered to rats. A heparinized syringe with a 25-gauge
needle was used to draw blood (approximately
0.20mL) from the left jugular vein at 0.083, 0.25,
0.5, 1, 2, and 3h after administration of MPC
(5.0mg·kg!1, n F 4), or at 0.083, 0.25, 0.5, 1, and
3h after administration of MPC (50mg·kg!1, n F
5–6). Before administration of either dose of MPC,
blood (approximately 0.20mL) was obtained from
each rat and used as the control. The blood was
centrifuged at 3,000g for 10min at 4°C to obtain
plasma. The plasma was transferred to another tube
and stored at !80°C until it was analyzed.
Sample pretreatment. For determining the
plasma concentration of MPC, 2 calibration curves
(31.25–250µM and 200–800µM) were constructed.
Ten microliters of PBS or rat blank plasma was
spiked with 10µL of 31.25–800µM MPC dissolved
in CH3CN and 10µL of 200µM I.S. dissolved in
CH3CN, and vigorously mixed with 70µL of CH3CN/
MeOH (50/50). In the case of plasma samples from
the rats administered MPC, 10µL of CH3CN was
used instead of MPC in CH3CN.
After centrifugation at 2,500rpm for 5min,
50µL of the supernatant was sampled and evapo-
rated in vacuo. The obtained residue was dissolved in
100µL of the mobile phase, 60µL (31.25–250µM) or
20µL (200–800µM) of the ﬁnal solution after ﬁltra-
tion with Durapore® (0.2µm membrane, Millipore
K.K., Tokyo, Japan), and was injected into the LC-
MS system.
Administration and determination of D-Trp
concentration. D-Trp was dissolved in PBS
(10mg·mL!1) and administered i.p. to control or
Ket-treated rats (100mg·kg!1; n F 3–5) at 30min
after i.p. administration of MPC (50mg·kg!1). A
heparinized syringe with a 25-gauge needle was used
to draw blood (approximately 0.20mL) from the left
jugular vein 0.5, 1, 1.5, 2, 3, 4, 5, and 6h after
administration of D-Trp. The blood was treated in
a similar manner as described in previous paper.17)
Plasma D-Trp concentration was determined by our
previously published HPLC method.17)
LC-MS conditions. The LC-MS apparatus
comprised an Agilent 1200 series HPLC (Agilent
Technologies, CA, U.S.A.) and a time of ﬂight
(TOF)-MS, JMS-T100 LP AccuTOF LC-Plus,
equipped with an electrospray ionization (ESI)
source (JEOL Co. Ltd., Tokyo, Japan). The separa-
tion column used in this study was TSKgel ODS-
80Ts QA (150mm # 2.0mm; i.d., 5µm) (Tosoh
Corporation, Tokyo, Japan). For the mobile phase,
0.1% HCO2Hi nH 2O/CH3CN (95/5) was eluted
isocratically at 0.16mL·min!1. Column temperature
was maintained at 40°C. The conditions for ESI-MS
detection were as follows: positive ion mode; needle
voltage was set at 2,000V; and the ring lens and
oriﬁce 1 and 2 voltages were set at 8, 49, and 4V,
respectively. Nitrogen was used as the nebulizing
and desolvating gas, and the pressure was constant
at 0.617MPa. The desolvation chamber and oriﬁce 1
temperatures were 250°C and 80°C, respectively. The
data were obtained using Mass Center software,
MS-56010MP (JEOL).
Precision and accuracy. The precision was
expressed as relative standard deviation (RSD, %),
and the accuracy was expressed as relative mean
error (RME, %). RSD and RME were calculated by
following equations [1] and [2], respectively.
RSD ð%Þ¼ð standard deviation=meanÞ 100 ½1 
RME ð%Þ¼½ ð measured concentration
  added ðtheoreticalÞ concentrationÞ
=added ðtheoreticalÞ concentration 
  100 ½2 
Pharmacokinetic parameters and statistical
analysis. Pharmacokinetic parameters obtained in
the present study were determined by a simplex
method analysis or moment analysis. Statistical
analyses were performed using a one-way analysis
of variance (ANOVA), followed by Bonferroni’s
multiple comparison test. A p value below 0.05 was
judged as a signiﬁcant diﬀerence.
Results and discussion
Plasma MPC concentration. In the present
study, LC-TOF/MS was employed for determination
of plasma MPC concentration in rats after its i.p.
administration. Figure 2(a) shows a representative
MS spectrum of a standard of MPC (0.4mM),
showing the m/z at 127.05. For determining MPC
concentration, a structural isomer of MPC, 3-
methylpyrazole-4-carboxylic acid (Fig. 1), was used
as the I.S. Under the present HPLC conditions, in
which the mobile phase was 0.1% HCO2Hi nH 2O/
CH3CN (95/5) with an ODS column (150 # 2.0mm;
i.d., 5µm), the I.S. and MPC peaks were found to be
separated and eluted at close retention times, i.e., 8.3
and 12.5min, respectively. Therefore, selected ion
monitoring (SIM) at m/z 127.05 showed that 2 clear
peaks were simultaneously detected (Fig. 2(b)). The
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(RSD) were in the range of !10.49% to 4.19% and
!8.86% to 4.36% (n F 4), and 0.61% to 2.85% and
0.55% to 2.91% (n F 4), respectively (Table 1).
Figure 2(c) shows the SIM at m/z 127.05 of the
blank plasma sample spiked with 10µL of MPC
(400µM) and I.S. (200µM), obtained by the pro-
posed LC-MS. Both MPC and I.S. peaks were clearly
detected, and the detection limit for MPC was
approximately 3.0pmol (100nM in plasma) on the
column (signal to noise ratio, 3). The 2 calibration
curves, which covered lower (31.25–250µM) and
higher concentration ranges (200–800µM), showed
good linearity (r2 F 0.9982 and 0.9996, respectively).
These validation data indicated that the present LC-
MS method, including the pretreatment procedure,
was suﬃcient for the determination of plasma MPC
concentration. Using the LC-MS, time-course proﬁles
of plasma MPC concentration in control and Ket-
treated rats, which are in part an animal model of
schizophrenia,9) were investigated after i.p. admin-
istration of MPC (5.0 or 50mg·kg!1). As shown in
Fig. 2(d), the MPC peak in rat plasma was clearly
detected at 5.0min after its administration (5.0
mg·kg!1).
Figure 3 shows time-course proﬁles of plasma
MPC concentration after its i.p. administration (5.0
or 50mg·kg!1). In the rat groups administered
the low dose (5.0mg·kg!1) of MPC, the maximum
concentration (Cmax) of plasma MPC was reached
at 0.5h in both control and Ket-treated rats.
Subsequently, similar declines were observed until
2h after administration. Between the control and
Ket-treated rats, no remarkable diﬀerences were
observed in PK parameters, such as Cmax, half-life
(t1/2), or area under the curve (AUC).
Previously, the PK parameters of plasma MPC
concentration in SD rats (p.o. and i.v. administra-
tion, 10mg·kg!1) were reported by Adage et al.16)
However, their previous data, especially the t1/2
(5.59h) and clearance (CL) (0.22L·h!1·kg!1), were
diﬀerent from our present data on the control rats
(t1/2, 50.8min and CL, 18.3L·h!1·kg!1). These dif-
ferences might be attributed to diﬀerences in the
Fig. 2. Representative mass spectrum of a standard of MPC (400µM) (a) and the selected ion monitoring at m/z 127.05 (b, c, d)
obtained by the LC-MS method. A standard of MPC (400µM) and I.S. (200µM) (b), a blank plasma sample spiked with 10µL of
MPC (400µM) and I.S. (200µM) (c), and a plasma sample at 5min after i.p. MPC administration (5.0mg·kg!1) (d), respectively.
Detailed conditions are described in the Materials and methods section.
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calculation method for the PK parameters.
When a high dose (50mg·kg!1) of MPC was
administered, plasma MPC concentrations were sig-
niﬁcantly increased than those in the case of a low
dose (5.0mg·kg!1) of MPC (p < 0.01). In addition, an
interesting phenomenon occurred. In the rat groups
that were administered the high dose, plasma MPC
concentrations at 5.0 and 15min in the Ket-treated
rats were signiﬁcantly higher than those in the
control groups (p < 0.01 and p < 0.05, respectively;
Fig. 3). After 1h, the MPC concentrations declined
similarly in both control and Ket-treated rats.
We therefore considered that plasma MPC
concentration might diﬀer between the control and
Ket-treated rats when a high dose of MPC is
administered. In the present study, samples from
Ket-treated rats were taken 4 weeks after cessation
of the repeated ketamine treatment. Therefore, we
assumed that ketamine and its major metabolite,
norketamine, were completely eliminated from the
rat body, because their half-lives in plasma are
approximately 0.5–0.6h and 0.6–0.8h, respec-
tively.22),23)
These ﬁndings suggest that the repeated Ket
treatment alters the expression of some proteins
responsible for the absorption, distribution, metabo-
lism, or elimination (ADME) of MPC. Based on the
signiﬁcant diﬀerence in the Cmax values that were
observed with the high dose of MPC, proteins
involved in the ADME of MPC, such as transporters
or metabolic enzymes, might be saturated by the high
dose of MPC. This suggests that the expression of
these proteins was reduced in the Ket-treated rats.
Thus, it is likely that deﬁciency of transporters, by
which MPC is incorporated into cells, caused the
observed increase in plasma MPC concentration.
The lack or attenuated expression of an enzyme
responsible for metabolizing MPC in cells might
increase the plasma MPC concentration. These
ﬁndings indicate that DAAO-inhibitory eﬀects of
MPC might be altered in the Ket-treated rats.
Table 1. Validation data on the determination of plasma MPC concentration in the ranges of 31.25–250µM and 200–800µM by the
proposed LC-MS method (n F 4, mean ’ S.D.)
Concentration spiked in plasma (µM) 31.25 62.5 125 250
Intra-day
mean ’ S.D. 27.97 ’ 0.80 64.65 ’ 1.57 130 ’ 1.96 248 ’ 3.35
RSD (%) 2.85 2.42 1.50 1.35
RME (%) !10.49 3.44 4.19 !0.92
Inter-day
mean ’ S.D. 28.48 ’ 0.81 62.68 ’ 0.91 130 ’ 3.79 244 ’ 6.63
RSD (%) 2.86 1.45 2.91 2.72
RME (%) !8.86 0.29 4.36 !2.41
200 400 600 800
Intra-day
mean ’ S.D. 191 ’ 1.17 406 ’ 5.21 614 ’ 15.2 787 ’ 7.40
RSD (%) 0.61 1.28 2.47 0.94
RME (%) !4.59 1.43 2.33 !1.58
Inter-day
mean ’ S.D. 196 ’ 5.18 403 ’ 8.91 602 ’ 5.76 786 ’ 4.33
RSD (%) 2.64 2.21 0.96 0.55
RME (%) !1.79 0.78 0.26 !1.70
Fig. 3. Time-course proﬁles of plasma MPC concentration after
i.p. administration of MPC to rats. Open triangles (control rats)
and closed squares (Ket-treated rats) with dotted lines represent
rats administered 5.0mg·kg!1 MPC (n F 4), and open (control
rats) and closed circles (Ket-treated rats) with solid lines
represent rats administered 50mg·kg!1 MPC (n F 5–6). * p <
0.05, ** p < 0.01, compared to control rats (50mg·kg!1). # p <
0.01, compared to control and Ket-treated rats (5.0mg·kg!1).
Plasma concentration of a DAAO inhibitor in ketamine-treated rats No. 10] 645Plasma D-Trp concentration. To test this
hypothesis, a representative D-amino acid, D-Trp,
was administered i.p. (100mg·kg!1) to the Ket-
treated rats after pre-administration of MPC
(50mg·kg!1), and we determined if changes in the
PK parameters of plasma D-Trp concentration
occurred in Ket-treated rats. D-Trp was chosen for
this experiment because it is easily metabolized by
DAAO, with a reported Km value of 845µM.21) After
30min of pretreatment with MPC or the vehicle,
D-Trp was administered to both control and Ket-
treated rats (100mg·kg!1). As shown in Fig. 4A and
B, the time-course proﬁles of plasma D-Trp concen-
tration in the control and Ket-treated rats without
MPC pretreatment (vehicle administration) were
almost identical, suggesting that ADME, including
the metabolism of D-Trp by DAAO, were not altered
in Ket-treated rats. However, in the rats pretreated
with MPC, a signiﬁcant diﬀerence in plasma D-Trp
concentration was observed between control and
Ket-treated rats. As shown in Fig. 4C and D, the
plasma D-Trp concentrations in Ket-treated rats
pretreated with MPC were signiﬁcantly lower than
those in the control rats pretreated with MPC.
Although no signiﬁcant diﬀerence in plasma D-Trp
concentration was observed between control and
Ket-treated rats (Fig. 4A and B), the plasma D-Trp
concentrations were signiﬁcantly higher in the con-
trol rats pretreated with MPC (Fig. 4A and C), while
there was no signiﬁcant increase in the plasma D-Trp
concentrations in Ket-treated rats pretreated with
MPC (Fig. 4B and D). We previously reported that
Fig. 4. Time-course proﬁles of plasma D-Trp concentration (left) and area under the curve of plasma D-Trp concentration (right)
(100mg·kg!1, n F 3–5). A: Proﬁles of plasma D-Trp concentration after i.p. administration of D-Trp to control rats without MPC
pretreatment, B: Proﬁles of plasma D-Trp concentration after i.p. administration of D-Trp to control rats with MPC pretreatment, C:
Proﬁles of plasma D-Trp concentration after i.p. administration of D-Trp to Ket-treated rats without MPC pretreatment, D: Proﬁles
of plasma D-Trp concentration after i.p. administration of D-Trp to Ket-treated rats with MPC pretreatment. * p < 0.05, ** p < 0.01,
compared to control rats with MPC pretreatment. # p < 0.05, compared to Ket-treated rats without MPC pretreatment. n.s.: not
signiﬁcant.
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creased in normal rats pretreated with MPC,17)
implying that MPC could inhibit D-Trp metabolism
by DAAO in vivo in normal rats. However, in the
Ket-treated rats, MPC did not inhibit D-Trp
metabolism by DAAO. The PK parameters of
plasma D-Trp concentration are summarized in
Table 2. Among the measured PK parameters of
plasma D-Trp concentration, Cmax and AUC were
signiﬁcantly diﬀerent between the MPC-pretreated
control and Ket-treated rats. As shown in Table 2,
MPC-pretreatment caused an increase in the Cmax
and AUC, and a decrease in the Vd in control rats,
suggesting that the DAAO-inhibitory eﬀect of MPC
normally occurred in these rats. In contrast, there
were no signiﬁcant diﬀerences in the PK parameters
in Ket-treated rats, with or without MPC pretreat-
ment, indicating that the DAAO-inhibitory eﬀect
induced by MPC might be quite absent. This
indicates that the DAAO-inhibitory eﬀect of MPC
was considerably attenuated in the Ket-treated rats.
These results suggest that the possibility of
decreased MPC metabolism in Ket-treated rats
should be ruled out, because the pharmacological
action of MPC was attenuated. Therefore, we
speculate that one of the reasons for the absence of
the DAAO-inhibitory eﬀect of MPC in the Ket-
treated rats was that the MPC was not suﬃciently
incorporated into the liver or kidney cells, which
possess relatively high DAAO activity, in Ket-
treated rats. This explanation is based on the result
that plasma MPC concentrations in Ket-treated rats
were signiﬁcantly higher than those in control rats
(Fig. 3).
It seems likely that D-Trp metabolism by DAAO
was not inhibited due to a decreased incorporation of
MPC into cells. This could explain why the DAAO-
inhibitory eﬀect of MPC was not observed in the Ket-
treated rats. Changes in expression of proteins that
are involved in the incorporation of MPC into the
liver or kidney will need to be examined in future
studies. Indeed, it has been reported that repeated
ketamine treatment could induce changes in the
expression of some proteins in rats.24),25)
As Ket-treated rats are, in part, an animal model
for schizophrenia,9) it is crucial to elucidate whether
these changes occur in patients with schizophrenia.
Conclusion
The proposed LC-MS method was used to
determine the concentration of a DAAO-inhibitory
compound, MPC, in rat plasma after its adminis-
tration. In Ket-treated rats, the Cmax value for
plasma MPC was signiﬁcantly higher than that
in the control rats following i.p. administration
(50mg·kg!1). This phenomenon was accompanied
by attenuation of the DAAO-inhibitory eﬀect of
MPC in Ket-treated rats.
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